Andrew L. Pecora, MD

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the role of stem cell transplant in patients with multiple myeloma.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The debate continues to rage over whether the difference in the cost of oncologic care between outpatient hospital and physician private offices is appropriate.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

Oncologists in private offices who supply chemotherapy and biologic infusion therapies for their patients have until recently been exempt from regulations that protect the workplace from aerosolized contaminating agents.

In community oncology, the complexity and cost of therapy and therapy administration have caused the cost of delivering a service to rise disproportionately relative to actual payment.

Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.

To optimize clinical outcomes and reduce the total cost of care, it is important to limit physicians’ choices of care.

Over the past 3 years, there has been a growing chorus of complaint about the rising costs of medications, particularly in oncology.

Genomics, proteomics, precision analytics, Big Data analysis, and artificial intelligence now in use or in late phases of development can help healthcare providers to achieve the promises of the Triple Aim of medicine: improve clinical outcomes for all, reduce total cost of care for the populations served, and improve patient experiences

The research presented at AACR focused on the fundamentals of cell biology, cell aging, and cell death; how the immune system recognizes and kills cancer cells; and how, in turn, cancer cells avoid immune system detection.

To get physicians to work together, an organizing structure is needed and the drive to create partnerships.

Andrew L. Pecora, MD, discusses his hopes for healthcare reform if the the Affordable Care Act is repealed.

The primary goal of a cancer diagnosis is to end up with the best possible outcome, and there are always several highways of care, or bundles, to choose from.

Over the past 30 years, I have regularly attended annual meetings of the American Society of Hematology, where experts from around the globe convene to share the latest advances.

It is almost unimaginable. Oncologists have waited for decades to offer their patients a better chance of surviving cancer, and now they can—for multiple cancer types.

We all know that healthcare is at a crossroads: to the left, there is rationed care, and to the right, you have economic insolvency, if we remain on our current course.

As the cost comes down due to new technologies and as studies mature, maybe the value equation for common malignancies will favor proton beam therapy. However, it is hard to imagine how throwing a house will ever be as cost-efficient as throwing a marble.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

We consider what we do to patients through prescription or procedure as a potential source of harm, followed less so by our behavior, when we fail to be caring or courteous.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, talked about the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and other aspects of healthcare reform.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Medicare Part B Drug Payment Model (OCM) and other aspects of healthcare reform.

CMS, through the Center for Medicare & Medicaid Innovation, has launched an initiative called the Oncology Care Model that is designed to maintain clinical outcomes and reduce the total cost of care. The obvious first question is, has it been designed to do so?

It seems to be that there is a "minor" disagreement between ASCO and CMS about the approach to address value in cancer care delivery.

Are the medicines of tomorrow, which are expected to cost in the hundreds of thousands of dollars, only going to be available to the privileged few or can we find solutions so they can be available to most of the population?

Consolidation in the insurance industry and the pace of the rise in cost of general and specialty pharmaceuticals are the 2 factors in the healthcare industry that will most affect access and affordability.